TY - JOUR
T1 - Cytolytic pathways in haematopoietic stem-cell transplantation
AU - Van den Brink, Marcel R.M.
AU - Burakoff, Steven J.
N1 - Funding Information:
We apologize to all researchers whose publications have not been cited owing to space constraints. This work was supported by a National Institutes of Health program project grant (S.J.B.) and an award of the Wendy Will Case Cancer Fund (M.R.M.B.). M.R.M.B is the recipient of Scholar awards of the Cancer Research Fund of the Damon Runyan-Walter Foundation, and the V Foundation.
PY - 2002/4
Y1 - 2002/4
N2 - The remarkable activity of donor T cells against malignant cells in the context of an allogeneic haematopoietic stem-cell transplantation (HSCT) is arguably, at present, the most potent clinical immunotherapy for cancer. However, alloreactive donor T cells are also important effector cells in the development of graft-versus-host disease (GVHD), which is a potentially lethal complication for recipients of an allogeneic HSCT. Therefore, the separation of the GVHD and graft-versus-tumour (GVT) activity of donor T cells has become a topic of great interest for many investigators. Recent studies have shown that donor T cells make differential use of their cytolytic pathways in mediating GVHD and GVT effects. Therefore, the selective blockade or enhancement of cytolytic pathways provides an intriguing therapeutic opportunity to separate the desired GVT effect from the potentially devastating GVHD.
AB - The remarkable activity of donor T cells against malignant cells in the context of an allogeneic haematopoietic stem-cell transplantation (HSCT) is arguably, at present, the most potent clinical immunotherapy for cancer. However, alloreactive donor T cells are also important effector cells in the development of graft-versus-host disease (GVHD), which is a potentially lethal complication for recipients of an allogeneic HSCT. Therefore, the separation of the GVHD and graft-versus-tumour (GVT) activity of donor T cells has become a topic of great interest for many investigators. Recent studies have shown that donor T cells make differential use of their cytolytic pathways in mediating GVHD and GVT effects. Therefore, the selective blockade or enhancement of cytolytic pathways provides an intriguing therapeutic opportunity to separate the desired GVT effect from the potentially devastating GVHD.
UR - https://www.scopus.com/pages/publications/0036550199
U2 - 10.1038/nri775
DO - 10.1038/nri775
M3 - Review article
C2 - 12001998
AN - SCOPUS:0036550199
SN - 1474-1733
VL - 2
SP - 273
EP - 281
JO - Nature Reviews Immunology
JF - Nature Reviews Immunology
IS - 4
ER -